Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a SAD Study of EC5026 in Healthy Subjects
NCT04228302Phase 1Completed
- Sponsor
- EicOsis Human Health
- Start
- Dec 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in neuropathic pain comparing EC5026 Arms with Placebo Arm (2 arms). Primary endpoints: Incidence of Adverse Events (AEs) at 14 days, Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration and 10 more. Started Dec 2019; status: completed.
02
Drugs
EC5026
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT04228302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228302.